2-Butyl-3-[[4-(2-iodophenyl)phenyl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one | 197440-06-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-Butyl-3-[[4-(2-iodophenyl)phenyl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one
• CAS: 197440-06-5
• 化学式: C₂₄H₂₇IN₂O
• 分子量: 486.396
• InChiKey: WPCIEDKRDUHQIR-UHFFFAOYSA-N

物化性质

• 沸点：
  567.5±60.0 °C(Predicted)
• 密度：
  1.43±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  32.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  氰化亚铜 、 2-Butyl-3-[[4-(2-iodophenyl)phenyl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one 以 N,N-二甲基甲酰胺 为溶剂， 以65%的产率得到厄贝沙坦烃化物
  参考文献：
  名称：

  Radiosynthesis of [tetrazoyl-11C]irbesartan, a non-peptidic angiotensin II antagonist

  摘要：

  With the aim of visualizing myocardial angiotensin II receptors (AT1 subtypes), [tetrazoyl-C-11]2-n-butyl-1-[(2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-yl)methyl]-4-spirocyclo-pentane-2-imidazoline-5-one ([tetrazoyl-C-11]irbesartan (SR47436/BMS-186295)) 11 was synthesized in one pot in four steps from [C-11]hydrogen cyanide. The labelling process which yielded [tetrazoyl-C-11]irbesartan is described in detail and could be applied to the labelling of other ligands which possess the (1H-tetrazol-5-yl) moiety. Positron emission tomography (PET) studies were performed in dogs. Heart, lung and blood time-activity curves did not change. Therefore this new radioligand is not suitable for studying myocardial angiotensin II receptors with PET.

  DOI：

  10.1016/s0223-5234(97)88917-9
• 作为产物：
  描述：

  1-(4-甲基苯基)-2-硝基苯 在 盐酸 、 氢氧化钾 、 N-溴代丁二酰亚胺(NBS) 、 sodium methylate 、 三氟乙酸 、 potassium iodide 、 tin(ll) chloride 、 sodium nitrite 、 过氧化苯甲酰 作用下， 以 甲醇 、 四氯化碳 、 水 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 82.0h， 生成 2-Butyl-3-[[4-(2-iodophenyl)phenyl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one
  参考文献：
  名称：

  Radiosynthesis of [tetrazoyl-11C]irbesartan, a non-peptidic angiotensin II antagonist

  摘要：

  With the aim of visualizing myocardial angiotensin II receptors (AT1 subtypes), [tetrazoyl-C-11]2-n-butyl-1-[(2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-yl)methyl]-4-spirocyclo-pentane-2-imidazoline-5-one ([tetrazoyl-C-11]irbesartan (SR47436/BMS-186295)) 11 was synthesized in one pot in four steps from [C-11]hydrogen cyanide. The labelling process which yielded [tetrazoyl-C-11]irbesartan is described in detail and could be applied to the labelling of other ligands which possess the (1H-tetrazol-5-yl) moiety. Positron emission tomography (PET) studies were performed in dogs. Heart, lung and blood time-activity curves did not change. Therefore this new radioligand is not suitable for studying myocardial angiotensin II receptors with PET.

  DOI：

  10.1016/s0223-5234(97)88917-9